



Cataplexy and/or EDS in Narcolepsy Indication Summary

xywav[®] 
(calcium, magnesium, potassium,
and sodium oxybates) oral solution 

XYWAV is the first and only lower-sodium oxybate FDA approved for the treatment of cataplexy and/or EDS in patients 7 years of age and older with narcolepsy.¹⁻³

XYWAV is **exclusively distributed by Express Scripts Specialty Distribution Services**, a consolidated distributor for both XYREM[®] (sodium oxybate) oral solution, 0.5 g/mL, and XYWAV.



NDC CODE ¹	PACKAGING ¹	WAC ⁴
One 180 mL bottle: 68727-150-01	<ul style="list-style-type: none">Each prescription includes XYWAV with an attached press-in bottle adaptor and an oral measuring device (plastic syringe)Each amber bottle contains XYWAV oral solution at a concentration of 0.5 g/mL and has a child-resistant cap	[\$6,590]

XYWAV has **131 mg** of sodium per maximum 9-g nightly dose^{1,3,5}

VS

High-sodium oxybates have **1,640 mg** of sodium per 9-g dose^{1,3,5}

Taking XYWAV over a high-sodium oxybate **reduces a patient's excessive sodium intake, a modifiable risk factor for CV disease**^{5,6}



To request a presentation from your Account Manager, please contact

See established [efficacy](#) and [safety](#) for XYWAV.

CNS=central nervous system; CV=cardiovascular; EDS=excessive daytime sleepiness; FDA=Food and Drug Administration; NDC=National Drug Code; WAC=wholesale acquisition cost.

Important Safety Information

WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE.

• Central Nervous System Depression

XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses. Many patients who received XYWAV during clinical trials in narcolepsy were receiving CNS stimulants.

• Abuse and Misuse

The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.

Because of the risks of CNS depression and abuse and misuse, XYWAV is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS.

Please see additional Important Safety Information on the next page and full [Prescribing Information](#), including BOXED Warning.

Contraindications

XYWAV is contraindicated in combination with sedative hypnotics or alcohol and in patients with succinic semialdehyde dehydrogenase deficiency.

Warnings and Precautions

- **CNS Depression:** Use caution when considering the concurrent use with other CNS depressants. If concurrent use is required, consider dose reduction or discontinuation of one or more CNS depressants (including XYWAV). Consider interrupting XYWAV treatment if short-term opioid use is required. After first initiating treatment and until certain that XYWAV does not affect them adversely, caution patients against hazardous activities requiring complete mental alertness or motor coordination such as operating hazardous machinery, including automobiles or airplanes. Also caution patients against these hazardous activities for at least 6 hours after taking XYWAV. Patients should be queried about CNS depression-related events upon initiation of XYWAV therapy and periodically thereafter.
- **Abuse and Misuse:** XYWAV is a Schedule III controlled substance. The rapid onset of sedation, coupled with the amnestic features of GHB, particularly when combined with alcohol, has proven to be dangerous for the voluntary and involuntary user (eg, assault victim).
- **Respiratory Depression and Sleep-Disordered Breathing:** XYWAV may impair respiratory drive, especially in patients with compromised respiratory function. In overdoses of oxybate and with illicit use of GHB, life-threatening respiratory depression has been reported. Increased apnea and reduced oxygenation may occur with XYWAV administration in adult and pediatric patients. A significant increase in the number of central apneas and clinically significant oxygen desaturation may occur in patients with obstructive sleep apnea treated with XYWAV. Prescribers should be aware that sleep-related breathing disorders tend to be more prevalent in obese patients, in men, in postmenopausal women not on hormone replacement therapy, and among patients with narcolepsy.
- **Depression and Suicidality:** In Study 1, the pivotal clinical trial in adult patients with narcolepsy (n=201), depression and depressed mood were reported in patients treated with XYWAV. In most cases, no change in XYWAV treatment was required. Two suicides and two attempted suicides occurred in adult clinical trials with oxybate (same active moiety as XYWAV). One patient experienced suicidal ideation and two patients reported depression in a pediatric clinical trial with oxybate. Monitor patients for the emergence of increased depressive symptoms and/or suicidality while taking XYWAV, which require careful and immediate evaluation.
- **Other Behavioral or Psychiatric Adverse Reactions:** Monitor patients for impaired motor/cognitive function or the emergence of or increase in anxiety and/or confusion. The emergence or increase in the occurrence of behavioral or psychiatric events in patients taking XYWAV should be carefully monitored.
- **Parasomnias:** In pivotal clinical trials, parasomnias including sleepwalking were reported in adult patients treated with XYWAV. Parasomnias, including sleepwalking, also have been reported in a pediatric clinical trial with sodium oxybate (same active moiety as XYWAV) and in postmarketing experience with sodium oxybate. Episodes of sleepwalking should be fully evaluated and appropriate interventions considered.

Most Common Adverse Reactions

In Study 1, the most common adverse reactions (incidence $\geq 5\%$ of XYWAV-treated patients) were headache, nausea, dizziness, decreased appetite, parasomnia, diarrhea, hyperhidrosis, anxiety, and vomiting.

In the pediatric clinical trial with XYREM (same active moiety as XYWAV) in patients 7 years of age and older with narcolepsy, the most common adverse reactions ($\geq 5\%$) were nausea (20%), enuresis (19%), vomiting (18%), headache (17%), weight decreased (13%), decreased appetite (9%), dizziness (8%), and sleepwalking (6%). The safety profile in pediatric patients with XYWAV is expected to be similar to that of adult patients treated with XYWAV and to that of pediatric patients treated with XYREM.

Please see full Prescribing Information, including **BOXED Warning.**

For more information on XYWAV, visit www.xywavhcp.com.

References: 1. XYWAV® (calcium, magnesium, potassium, and sodium oxybates). Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc. 2. Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. *CNS Drugs*. 2020;34(1):9-27. 3. Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. *Sleep*. 2021;44(3):zsaa206. 4. Data on File-REF-21017. Jazz Pharmaceuticals, Inc. 5. XYREM® (sodium oxybate). Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc. 6. US Department of Health and Human Services, US Food and Drug Administration website. Clinical superiority findings. Updated December 18, 2024. Accessed March 12, 2025. <https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings>.

XYWAV and XYREM are registered trademarks of Jazz Pharmaceuticals, Inc.